Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

2.690 +0.260 (+10.70%)
Streaming Delayed Price Updated: 2:30 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
Via Benzinga
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Recap: Fate Therapeutics Q4 Earnings
Via Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for Fate Therapeutics
Via Benzinga
Recap: Fate Therapeutics Q3 Earnings
Via Benzinga
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
A Preview Of Fate Therapeutics's Earnings
Via Benzinga
Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18
Via Investor Brand Network
Analyst Ratings for Fate Therapeutics
Via Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock
Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%. 
Via InvestorPlace
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
From Fate Therapeutics, Inc.
Via GlobeNewswire
Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Latest Analyst Ratings for Fate Therapeutics
Via Benzinga
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at Upcoming September Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 46 stocks hit new 52-week lows. 
Via Benzinga
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
From Kahn Swick & Foti, LLC
Via Business Wire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Why Shares of Fate Therapeutics Soared This Week
The company's shares bounced back after a stock sale last week. 
Via The Motley Fool
Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.